All In Biotech

Drug Trial Radar · NCT03905148

Study of the Safety and Pharmacokinetics of BGB-283 (Lifirafenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors

A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jan 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

91

Actual

Start

May 1, 2019

Primary completion

Oct 9, 2024

Study completion Oct 23, 2025

Sponsor

Lead sponsor
BeiGeneBeOne Medicines (BeiGene) (ONC)
Sponsor type
Industry
Collaborators
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
First posted
Apr 5, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part Phase 1b study of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) combination in participants with tumors.

Conditions

  • Solid Tumor, Adult

Interventions

  • LifirafenibDrug

    RAF Dimer Inhibitor

  • mirdametinibDrug

    MEK Inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events and Serious Adverse EventsTime frame: Approximately 2 years from date of the participants enrollment
  2. The incidence of DLT events and treatment-emergent AEs (TEAEs)Time frame: Approximately 2 years from date of the participants enrollment
  3. Objective response rate based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in participants with selected tumor typesTime frame: Approximately 2 years from date of the participants enrollment

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • University of California Los Angeles

    Santa Monica, California

  • MD Anderson

    Houston, Texas

  • Blacktown Cancer and Haematology Centre

    Blacktown, New South Wales, Australia

  • The Prince of Wales Private Hospital - Specialist Medical Randwick

    Randwick, New South Wales, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.